(Q24311643)

GOA release 2020-03-11

lipoprotein transport

1 reference

GOA release 2020-03-11

author

Arnold von Eckardstein

7

object named as

Arnold von Eckardstein

0 references

Thomas Lüscher

10

object named as

Thomas F Lüscher

0 references

Massimo Volpe

9

object named as

Massimo Volpe

0 references

author name string

Elena Osto

1

0 references

Alexei Kouroedov

2

0 references

Pavani Mocharla

3

0 references

Alexander Akhmedov

4

0 references

Christian Besler

5

0 references

Lucia Rohrer

6

0 references

Sabino Iliceto

8

0 references

Francesco Cosentino

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

11

0 references

language of work or name

English

0 references

publication date

18 November 2008

0 references

published in

Circulation

0 references

volume

118

0 references

page(s)

2174-82

0 references

issue

21

0 references

cites work

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Molecular understanding of hyperglycemia's adverse effects for diabetic complications

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Protein kinase C-beta inhibition and diabetic microangiopathy: effects on endothelial permeability responses in vitro

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Macrophage-restricted molecules: role in differentiation and activation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

PKC-B inhibition: a new therapeutic approach for diabetic complications?

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Inhibition of protein kinase C by N-myristoylated peptide substrate analogs

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

The macrophage foam cell as a target for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Class A scavenger receptor-mediated adhesion and internalization require distinct cytoplasmic domains

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Immunodeficiency in protein kinase cbeta-deficient mice

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Role of Monocytes in Atherogenesis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized cl

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021

The effect of ruboxistaurin on nephropathy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.108.789537

7 January 2021